ICW Investment Advisors LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 1.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,166 shares of the company’s stock after buying an additional 379 shares during the period. Novo Nordisk A/S comprises 1.2% of ICW Investment Advisors LLC’s holdings, making the stock its 28th largest position. ICW Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,274,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of NVO. WASHINGTON TRUST Co acquired a new stake in Novo Nordisk A/S in the 1st quarter valued at about $27,000. Patriot Financial Group Insurance Agency LLC acquired a new stake in Novo Nordisk A/S in the 1st quarter valued at about $30,000. TD Capital Management LLC acquired a new stake in Novo Nordisk A/S in the 1st quarter valued at about $30,000. Westside Investment Management Inc. acquired a new stake in Novo Nordisk A/S in the 1st quarter valued at about $36,000. Finally, Evolution Wealth Advisors LLC lifted its stake in Novo Nordisk A/S by 1,551.2% in the 4th quarter. Evolution Wealth Advisors LLC now owns 677 shares of the company’s stock valued at $39,000 after purchasing an additional 636 shares during the last quarter. Institutional investors and hedge funds own 6.69% of the company’s stock.
Several equities research analysts recently issued reports on NVO shares. Bank of America upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Morgan Stanley restated an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Monday, May 18th. ValuEngine upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Cowen assumed coverage on shares of Novo Nordisk A/S in a research report on Monday, May 4th. They set a “market perform” rating and a $72.00 price objective for the company. Finally, UBS Group downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, May 11th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $163.55.
Shares of NVO traded down $0.36 during mid-day trading on Monday, hitting $65.58. 52,898 shares of the company’s stock were exchanged, compared to its average volume of 1,355,521. Novo Nordisk A/S has a 52 week low of $46.92 and a 52 week high of $66.02. The stock’s 50-day simple moving average is $63.18 and its 200-day simple moving average is $59.80. The firm has a market cap of $154.15 billion, a price-to-earnings ratio of 25.70, a price-to-earnings-growth ratio of 2.39 and a beta of 0.46. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.05.
Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, May 6th. The company reported $0.75 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.07. Novo Nordisk A/S had a net margin of 31.91% and a return on equity of 73.87%. The company had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.70 billion. Analysts forecast that Novo Nordisk A/S will post 2.67 earnings per share for the current fiscal year.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Featured Article: What is a Tariff?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.